WESPAC Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-38,011
Closed -$3.64M 167
2018
Q3
$3.64M Buy
38,011
+4,426
+13% +$429K 2.13% 3
2018
Q2
$3.2M Buy
33,585
+5,486
+20% +$504K 3.3% 2
2018
Q1
$2.46M Buy
28,099
+14,219
+102% +$1.3M 1.51% 23
2017
Q4
$1.18M Sell
13,880
-13,746
-50% -$1.15M 1.09% 35
2017
Q3
$2.39M Buy
+27,626
New +$2.21M 1.58% 24

Other funds holding XBI

WESPAC Advisors's XBI Position: Q4 2018 in Review

WESPAC Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2018, closing a stake of 38,011 shares — an estimated $3.64M sold.

WESPAC Advisors first reported a position in XBI in Q3 2017 and held it in 5 quarters. The position peaked at $3.64M in Q3 2018. 427 funds tracked by Wall St. Rank hold XBI as of Q4 2018.

  • WESPAC Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2018 after selling out during the quarter.
  • WESPAC Advisors sold 38,011 State Street SPDR S&P Biotech ETF shares in Q4 2018, an estimated $3.64M.
  • WESPAC Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q3 2017 and held it in 5 quarters.
  • WESPAC Advisors's State Street SPDR S&P Biotech ETF position peaked at $3.64M in Q3 2018.
  • 427 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2018.

Based on WESPAC Advisors's 13F filing for Q4 2018, filed 31 Jan 2019.